FMP
Rubius Therapeutics, Inc.
RUBY
NASDAQ
Inactive Equity
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
0.057 USD
0.0015 (2.63%)
RUBY Financial Statements
Year
2022
2021
2020
2019
Current Assets
20.2M
229.82M
181.51M
289.27M
Cash & Short Term Investments
18.93M
225.85M
176.29M
283.29M
Cash And Cash Equivalents
14.87M
225.85M
91.17M
91.9M
Short Term Investments
4.07M
0
85.12M
191.39M
Net Receivables
0
0
0
0
Inventory
0
0
0
0
Other Current Assets
1.26M
3.98M
90.35M
197.37M
Non-Current Assets
2.88M
88.2M
96.28M
105.58M
Property, Plant & Equipment
2.83M
86.63M
94.4M
103.48M
Goodwill And Intangible Assets
0
0
0
0
Goodwill
0
0
0
0
Intangible Assets
0
0
0
0
Long Term Investments
0
0
0
0
Tax Assets
0
0
0
0
Other Non-Current Assets
50k
1.57M
1.88M
2.09M
Other Assets
0
0
0
0
Total Assets
23.07M
318.02M
277.79M
394.84M
-
-
-
-
Current Liabilities
7.94M
34.66M
27.84M
33.76M
Accounts Payable
1.23M
11.57M
5.48M
7.18M
Short Term Debt
1.1M
9.02M
8.95M
10.54M
Tax Payables
0
0
0
0
Deferred Revenue
0
13.4M
12.86M
15.72M
Other Current Liabilities
5.61M
14.07M
13.42M
16.04M
Total Current Liabilities
7.94M
34.66M
27.84M
33.76M
Total Non-Current Liabilities
0
104.58M
108.39M
86.87M
Long-Term Debt
0
104.44M
107.71M
86.46M
Deferred Revenue
0
0
0
0
Deferred Taxes Liabilities
0
0
0
0
Other Non Current liabilities
0
135k
688k
405k
Total Liabilities
7.94M
139.24M
136.23M
120.63M
Other Liabilities
0
0
0
0
Stockholders Equity
15.13M
178.78M
141.56M
274.21M
Common Stock
90k
90k
81k
80k
Retained Earnings
-856.68M
-677.02M
-480.47M
-312.74M
Accumulated Other Comprehensive Income/Loss
0
0
4k
75k
Other Shareholders Equity
871.73M
855.71M
621.95M
586.8M
Total Liabilities and Stockholders Equity
23.07M
318.02M
277.79M
394.84M
Retained Earning Schedule
Year
2022
2021
2020
2019
Retained Earnings (Previous Year)
-677.02M
-480.47M
-312.74M
-150.08M
Net Income
-230.86M
-188.82M
-162.04M
-160.46M
Stock Repurchases
0
0
0
-122k
Dividend Paid
0
0
0
0
Retained Earnings
-856.68M
-677.02M
-480.47M
-312.74M
Other Distributions
-179.67M
-196.55M
-167.73M
-162.78M
PPE Schedule
Year
2022
2021
2020
2019
Gross PPE
2.83M
86.63M
94.4M
103.48M
Annual Depreciation
6.25M
7.72M
5.69M
3M
Capital Expenditure
-5.3M
-3.65M
-5.5M
-40.66M
Net PPE
1.88M
82.55M
94.2M
141.15M
Intangible and Goodwill Schedule
Year
2022
2021
2020
2019
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
